A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD by Biria, Marjan et al.
European Neuropsychopharmacology (2019) 29, 905–913 
www.elsevier.com/locate/euroneuro 
A cross sectional study of impact and 
clinical risk factors of 
antipsychotic-induced OCD 
Marjan Biria a , b , 1 , Fiona-Xiaofei Huang c , 1 , Yulia Worbe d , e , f , 
Naomi A. Fineberg g , h , Trevor W. Robbins a , b , 
Emilio Fernandez-Egea a , i , j , ∗
a Behavioural and Clinical Neuroscience Institute, University of Cambridge, UK 
b Department of Psychology, University of Cambridge, UK 
c Fulbourn Hospital, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK 
d Sorbonne Université, Paris 05, France 
e Department of Neurophysiology, Saint-Antoine Hospital, Paris, France 
f INSERM U 1127, CNRS UMR 7225, Institute du Cerveau et de la Moelle Epinière, Paris, France 
g Hertfordshire Partnership University NHS Foundation Trust, University of Hertfordshire, Welwyn 
Garden City, UK 
h Postgraduate Medical School, University of Hertfordshire, Hatﬁeld, UK 
i Clozapine clinic, Cambridgeshire and Peterborough NHS Foundation Trust, Cambridge, UK 
j Department of Psychiatry, University of Cambridge, UK 
Received 7 February 2019; received in revised form 7 June 2019; accepted 10 June 2019 
KEYWORDS 
Obsessive compulsive 
disorder; 
Schizophrenia; 
Antipsychotic; 
Clozapine 
Abstract 
A large proportion of schizophrenia patients treated with second generation antipsychotics will 
develop Obsessive Compulsive Disorder (OCD). However, there are few studies about the im- 
pact of this comorbidity and who is at higher risk. In this study of clozapine-treated patients, 
we aimed to determine the impact on outcome of clozapine-induced OCD, as well as the clini- 
cal and sociodemographic risk factors related to OCD-onset in clozapine patients. We had strict 
and novel inclusion criteria to minimise mis-identiﬁcation of cases. The Obsessive-Compulsive 
Inventory-Revised (OCI-R) was used to divide 231 clozapine-treated patients into extreme cases 
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of OCD (OCI ≥ 24 or checking subscale ≥6) versus non-OCD (OCI < 15 and checking subscale 
< 4). The Global Assessment of Functioning (GAF), short version of Warwick-Edinburgh Wellbe- 
ing scale and Clinical Global Impression for schizophrenia (CGI) scales were used to determine 
outcome. Socio-demographic information was used to identify the risk factors for OCD devel- 
opment. We found that schizophrenia patients with OCD symptoms had a signiﬁcantly lower pa- 
tient rated wellbeing scores ( p < 0.001) only (no difference in clinician rated wellbeing scores), 
higher CGI positive ( p < 0.01) and higher CGI depressive scores ( p < 0.05). The only risk factors 
that reached signiﬁcance level were higher treatment dose ( p < 0.01) and younger paternal age 
at birth ( p < 0.05). There is scope for future studies based on e.g. imaging and genetic studies 
to further investigate causality, and in improving clinician screening for OCD. 
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY 
license. ( http://creativecommons.org/licenses/by/4.0/ ) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1. Introduction 
Schizophrenia and obsessive-compulsive disorder (OCD) are
frequently comorbid ( McGlashan, 1984 ). Several studies
have shown that schizophrenia patients treated with sec-
ond generation antipsychotics will develop symptoms of
obsessive-compulsive disorder (OCD) ( Schirmbeck and Zink,
2012 ) with the proportion being around half ( Fernandez-
Egea et al., 2018 ). To date, no replicated clinical risk factors
have been found that help to identify vulnerable cases prior
to treatment initiation. The clinical impact of this comor-
bidity on the patients’ social functioning and quality of life
is largely unknown. 
Indeed, studies investigating patient outcome and level
of functioning in antipsychotic induced OCD are sparse and
need further clariﬁcation ( de Haan et al., 2013; Frias et al.,
2014; Kim et al., 2015; Mukhopadhaya et al., 2009; Seng
et al., 2018; Üçok et al., 2014 ). Studies have shown lower
scores in self rated and foreign rated measures of well-
being in those cases with antipsychotic-induced OCD com-
pared to those without, with higher depressive symptoms,
suicidality, hospitalisation, poorer physical and psycholog-
ical health ( de Haan et al., 2013; Kim et al., 2015; Seng
et al., 2018; Üçok et al., 2014 ). In addition, interpersonal
relationship scores were lower in those with OCD ( Üçok et
al., 2014 ) and OCD cases may also show more motor symp-
toms ( Mukhopadhaya et al., 2009 ). Alternatively, one study
showed no signiﬁcant difference in outcome measures ( Frias
et al., 2014 ) when using foreign rated measures such as the
Quality of Life Scale. Some studies which have investigated
cognitive outcomes eg with an fMRI approach and in longitu-
dinal studies ( Schirmbeck et al., 2013 , 2015 ) found speciﬁc
and longitudinally stable cognitive impairments associated
with OCD comorbid schizophrenia. 
Therefore, further studies of larger and well charac-
terised samples are needed. 
There are no reliable clinical risk factors identiﬁed for
developing OCD that can help the clinician to predict who
will be at greater risk. Indeed, even the exact mechanism
and prevalence of antipsychotic-induced OCD remain un-
clear. Those antipsychotics with greater anti-serotoninergic
action, such as clozapine and olanzapine, have been more
often associated with OCD onset ( Poyurovsky et al., 2001;
Schirmbeck et al., 2011 ). The prevalence ranges from less
than 5% ( Mahendran et al., 2007 ) to 74% ( Schirmbeck et
al., 2011 ), reﬂecting not only different methodologies usedbut also the differences in the clinical samples included.
However, only a few of these studies ( Fontenelle et al.,
2012; Poyurovsky et al., 2005 ) were investigating OCD risk
factors speciﬁcally in cohorts of schizophrenia patients, and
they had limited sample size. Fontenelle et al. (2012) found
greater severity of depression and family history of OCD in
the cohort with comorbid OCD. Poyurovsky et al. (2005) also
found that relatives of OCD-schizophrenia patients had
higher morbid risk. Recent study also pointed to the pos-
sibility of co-prevalence of motor disorders prior to OCD
development in psychotic disorders ( Fineberg et al., 2017;
Swets et al., 2018 ). Nevertheless, these ﬁndings need fur-
ther replication in larger samples. 
It is likely that antipsychotic-induced OCD and ‘pure’ OCD
might share risk factors such as genetic, neurodevelopmen-
tal, immune and perinatal triggers. Demographic risk fac-
tors for ‘pure’ OCD include advanced maternal ( Chudal et
al., 2017; Steinhausen et al., 2013 ) and paternal age ( Wu
et al., 2012 ), perinatal events such as preterm birth, pro-
longed birth, low birth weight, breech, caesarean and for-
ceps deliveries ( Brander et al., 2016; Sampaio et al., 2009 ).
Cross sectional population studies suggested that gender
modulated the risk of OCD onset according to age with the
highest risk in adolescent males ( Steinhausen et al., 2013 )
and adult females ( Crum and Anthony, 1993; Fontenelle and
Hasler, 2008 ). Later in life, social factors such as social iso-
lation, previous physical abuse ( Grisham et al., 2011 ), ma-
ternal overprotection ( Wilcox et al., 2008 ) and drugs, espe-
cially cocaine and cannabis ( Crum and Anthony, 1993 ) mis-
use were recognised as risk factors for ‘pure’ OCD. There
is a substantial body of work exploring genetic risk fac-
tors. Multiple candidate genes have been found for ‘pure’
OCD ( Mattheisen et al., 2015 ) and associations with candi-
dates such as the SLC1A1 gene has been found in both pri-
mary and antipsychotic associated OCD. This has however
been difﬁcult to replicate in follow up studies across ethnic-
ities ( Schirmbeck and Zink., 2013 ). In addition, genes have
been found which share polygenic risk with both OCD and
schizophrenia ( Costas et al., 2016 ) 
One potential explanation of the lack of clinical risk fac-
tors for developing OCD in antipsychotic-treated patients
could be the mis-identiﬁcation of cases. In a recent re-
port by Fernandez-Egea et al. (2018) using a large cohort of
clozapine treated patients, we identiﬁed a few factors that
might have acted as confounders in prior studies. For in-
stance, we found rising OCD prevalence and checking com-
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culsion to be associated with increasing years of treatment. 
evelopment of OCD in this cohort could be a combination
f underlying vulnerability and anti-psychotic treatment, so 
t is possible that a patient without OCD after 5 years of
reatment might still be mis-identiﬁed as non-case despite 
oing on to develop OCD later. We also found that psychosis
everity correlated with OCD and obsessions severity which 
ould potentially over-represent OCD cases in those more 
oridly psychotic. Such distinctions have barely been con- 
idered in prior studies of the sociodemographic and clinical 
isk factors of antipsychotic-induced OCD. 
Our aims for this study were to a) determine if comorbid
CD is associated with a poorer outcome measures such as 
lobal functioning and subjective wellbeing, and b) identify 
he clinical and sociodemographic factors associated with 
ntipsychotic-induced OCD. We used the electronic records 
f a large cohort of clozapine treated patients who were 
arefully clinically phenotyped, including using standard- 
sed scales for OCD. In order to maximise the group differ-
nces, decided on a strategy of selecting the two ends of
he clinical phenotype (with and without OCD) of clozapine- 
reated patients as this drug is more strongly associated 
ith OCD-onset. We then performed a whole sample analy- 
is as a conﬁrmatory step. 
. Experimental procedures 
t is of note that we covered the prevalence and complex phe-
omenology of obsessions and compulsions in clozapine-treated pa- 
ients in a previous work ( Fernandez-Egea et al., 2018 ). Here, we
se the term OCD to deﬁne these phenomena, albeit acknowledging
he open debate about its pathophysiology and correct terminology.
.1. Study design 
his is a cross sectional, single centre study of a cohort of clozap-
ne treated patients at the Cambridgeshire and Peterborough NHS 
oundation Trust. The study included anonymised electronic clini- 
al records of all cases from August 2015 to April 2018, embedded
n an ethically approved database for research and clinical purposes
13/EE/0121). All cases were reviewed by the same care consultant
EFE). 
.2. Participants 
he clinical records of all schizophrenia patients treated with cloza-
ine were initially included in this study. 
.3. Assessment 
outine clinical assessments are described elsewhere ( Fernandez- 
gea et al., 2018 ) and include full psychiatric history, comprehen-
ive mental state examination, current medication list, smoking 
abit, legal and illegal drug history, early life history, clozapine
reatment length and side effects assessment and physical health
ssessment. Among others, psychopathological scales included as- 
essment for general functioning [Global Assessment of Functioning 
GAF)]( Haro et al., 2003 ), short version of the Warwick-Edinburgh
ellbeing Scale [SWEWBS]( Brown et al., 2016 ) and symptom sever-
ty using the Clinical Global Impression (CGI) for Schizophrenia 
 Busner and Targum, 2007 ) which includes 5 domains (positive, neg-
tive, cognitive, and depressive) rating from 1 to 7 for absence to
xtreme severity. The Obsessive-Compulsive Inventory Revised version (OCI-R) was 
he questionnaire used for determining cut off scores for OCD
iagnosis ( Foa et al., 2002 ). This widely used 18 item self-rated
uestionnaire is done annually in these patients. Each question has
 ﬁve-point Likert-type score measuring the degree of distress ex-
erienced with common OCD phenomena (not at all to extremely).
t also contains six sub-scales measuring severity for obsessions,
hecking, washing, hoarding, neutralising and ordering. A cut-off
f 21 for the total scale or above 5 for subscales is considered for
CD diagnosis ( Foa et al., 2002 ). In a previous study, we showed
hat OCI-R and its six-factor component had a valid goodness-of-ﬁt
nd structure in clozapine-treated patients ( Fernandez-Egea et al.,
018 ). 
.4. Inclusion and exclusion criteria 
he exclusion criteria were: 1) cases with no primary psychotic dis-
rder (off label use of clozapine), 2) those cases in which docu-
ented OCD predated clozapine use and 3) and cases that neither
howed clear OCD symptoms nor had a clear absence of OCD symp-
oms. The latter criterion was set to maximise the group differ-
nces and reduce false positives and we selected the two ends of
he clinical phenotype (with and without OCD). We considered the
uration of treatment, severity of the obsessive-compulsive symp- 
oms and the checking symptoms severity, as they are the most
ommonly reported symptoms. Length of clozapine treatment was 
elevant as some might have not yet expressed the vulnerability. In
his study, OCD was considered if an OCI-total score ≥ 24 or check-
ng subscale ≥ 6 regardless of treatment duration. Whereas an OCI-
otal score < 15, checking subscale < 4, no treatment for OCD, and a
reatment duration longer than 5 years for the non-OCD group were
onsidered. To note, we used a more strict score criteria for OCD,
f 24 instead of 21, in order to include cases with uncontroversial
CD diagnosis. 
.5. Statistical analysis 
ll statistical analyses were conducted using SPSS v23.0, with a
wo-tail 0.05 signiﬁcance level and R studio Version 1.0.136. Data
re presented as mean ( M ) and standard deviation (SD). Two in-
ependent data analyses were performed as follows: the impact
f developing antipsychotic-induced OCD was assessed comparing 
lobal functioning and subjective wellbeing using a series of Mul-
ivariate ANOVAs (MANOVA). To identify the risk factors for devel-
ping OCD, we used the following list of potential risk factors for
oth antipsychotic-induced OCD and general OCD literature: pater- 
al and maternal age, birth weight, hand dominance, family his-
ory of psychosis and OCD, age at presentation of schizophrenia,
ender, treatment dose and duration, smoking habit, comorbidities 
ith other psychiatric disorders and whether or not the psychosis
as initially triggered by drug use. For this part of the analysis, we
sed 2-tailed Students t-tests for normally distributed continuous
ata, Mann–Whitney U test for not normally distributed continuous
ata and χ2 test for categorical variables and a MANOVA according
o the analysis needs. A conﬁrmatory analysis was conducted with
he whole sample using a Multivariate Linear regression. 
. Results 
he database contained two hundred thirty-one patients 
n clozapine with primary diagnosis of non-affective psy- 
hosis. Of those, seventy-four were missing the OCI-R scores 
nd were not included in the analysis. Eight patients were
xcluded due to prior OCD diagnosis. One patient was ex-
luded due to conﬁrmed learning disability. 
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Table 1 Description of the risk factors. 
OCD Non-OCD p 
N 56 29 
Age at presentation ( M ± SD) 21.36 ± 4.9 21.34 ± 5.9 0.518 
Gender male (%) 75 86.2 0.275 
Father’s age at birth ( M ± SD) 29.6 ± 6.11 33.52 ± 8 0.028 ∗
Mother’s age at birth ( M ± SD) 27.02 ± 5.06 30.17 ± 6.33 0.056 
Treatment dose ( M ± SD) 349.55 ± 123.35 264.66 ± 144 0.006 ∗∗
Treatment duration ( M ± SD) 16 ± 7.7 16.14 ± 6.24 0.951 
Low birth weight (%) 8.9 a 6.9 a 0.786 
Current smoking (%) 32.1 31 0.56 
Comorbidities (%) 0.667 
Depression/schizoaffective disorder 10.7 6.9 
Anxiety/panic/phobia 5.4 10.3 
PTSD 0 3.4 
Drug/alcohol misuse 5.4 10.3 
Family history (%) 0.728 
Psychosis/bipolar disorder in 1st degree relatives 12.5 24.1 
OCD/affective disorders in 1st degree relatives 14.3 10.3 
Psychosis/bipolar disorder in 2nd degree relatives 10.7 6.9 
Hand dominance (%) 0.261 
Right 76.8 69 
Left 17.9 20.7 
Both 5.4 3.4 b 
Psychosis triggered by drug use (%) 46.4 48.3 0.733 
Type of presentation (%) 0.052 
Hallucination/delusion 94.6 79.3 
Psychosis part of mania/affective disorder 1.8 10.3 
Non-positive presentation 0 6.9 
Unknown 3.6 3.4 
Note : p represents p -signiﬁcance group differences (OCD vs non-OCD) using student’s t for father’s age at birth, treatment dose and 
duration, Mann–Whitney U for mother’s age at birth and age at presentation, and the χ2 test for gender, low birth weight ( < 2500 g), 
current smoking, comorbidities, family history, hand dominance, psychosis triggered by drug use, and type of presentation. 
a 24 out of 56 patients in the OCD group and 11 out of 29 patients in the non-OCD group did not have their birth-weight information. 
b Handedness information of two patients in the non-OCD group were missing. The signiﬁcance levels of p < 0.05 and p < 0.01 
are indicated with one and two stars respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Sixty-three patients were excluded for having an OCI-R
total score between 15 and 24 and/or a checking subscale
score between 4 and 6. The ﬁnal sample of 85 participants
consists of 29 schizophrenia patients without OCD symp-
toms (4 females, 25 males; mean age = 45.24, SD = 12.66,
range: 27–70 years) and 56 patients with OCD symptoms
(14 females, 42 males; mean age 48.29 SD = 9.76, range:
29–69 years). Eleven out of 56 patients in the OCD group
and 6 out of 29 patients in the non-OCD group were missing
their parent’s age at birth. Two participants in the non-OCD
group were missing the hand dominance data. 11 patients
in the non-OCD group and 24 in the OCD group did not know
their birth weights. 17 participants without OCD and 31
with OCD symptoms could not provide their family history.
Table 1 shows the descriptive statistics and the signiﬁcance
values for differences between OCD and non-OCD groups
for all variables. 
3.1. Impact of antipsychotic-induced OCD in 
patient rated wellbeing and functioning 
A series of MANOVA were conducted to assess the impact
of OCD versus no-OCD (independent variable) on the GAF,CGI-Positive, CGI-Negative, CGI-Depressive, CGI-Cognitive,
CGI-Overall, and the Wellbeing scores. 
The results ( Fig. 1 ) show a signiﬁcant effect of group on
wellbeing scores, F (1, 83) = 22.017, p < 0.001. Patients
with OCD symptoms had a lower wellbeing score ( M = 21.95,
SD = 4.33) compared with the non-OCD group ( M = 27.10,
SD = 5.60). The presence of OCD also had a signiﬁcant ef-
fect on the CGI-Positive scores, F (1) = 18.48, p < 0.01).
There were higher scores in the OCD-schizophrenia group
( M = 3.0, SD = 1.44) compared with the schizophrenia group
without OCD ( M = 2.0, SD = 1.47). In addition, the MANOVA
results showed that belonging to OCD versus non-OCD
group also inﬂuenced the CGI-Depressive scores signiﬁ-
cantly, F (1) = 4.046, p < 0.05, with higher depressive scores
in schizophrenia-OCD group ( M = 2.8, SD = 1.16) compared
with the other group without OCD ( M = 2.97, SD = 1.57).
There was no effect of group on the GAF and the CGI-
Negative scores. Table 1 shows the MANOVA results for all
variables. 
3.2. Risk factors for developing OCD 
Next, we were interested to understand the clinical and
sociodemographic factors associated with antipsychotic-
A cross sectional study of impact and clinical risk factors of antipsychotic-induced OCD 909 
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A
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Fig. 1 (A) Shows the average scores on different subsets of the Clinical Global Impression (CGI) scale. (B) Shows the average 
scores on the Global Assessment of Functioning (GAF) rated by clinicians and the Wellbeing scores rated by patients themselves. 
The Wellbeing scores are converted to percentages. The signiﬁcance levels of p < 0.05, p < 0.01, and p < 0.001 are indicated with 
one, two and three stars respectively. 
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e  nduced OCD. A 2-tailed Students t -test was used to examine
he impact of parents’ age, treatment dose and duration on 
he OCD symptoms development since these variables were 
ontinuous and normally distributed. 
There were signiﬁcant differences between groups for 
he father’s age at birth and the treatment dose. Signif-
cantly more patients with OCD symptoms had a younger 
ather at birth ( M = 29.60, SD = 6.11) and a higher treat-
ent dose ( M = 349.5,SD = 123.35) compared to those with-
ut OCD symptoms who had an older father ( M = 33.52,
D = 8) and were on a lower dose ( M = 264.66, SD = 144),
he t -test results are respectively t (66) = 2.25, p = 0.028nd t (83) = 2.84, p < 0.01. However, there was no signif-
cant difference between groups for the number of years
hey have been treated with clozapine t (83) = −0.062,
 = ns. 
A Mann–Whitney U test was performed to assess the asso-
iations between belonging to each group and the mother’s
ge at birth and the patient’s age at ﬁrst presentation of
sychosis since these variables were continuous and not nor-
ally distributed. The mother’s age at birth was lower in
he OCD group ( M = 27.02; SD = 5.06) compared with the
on-OCD schizophrenia group ( M = 30.17; SD = 6.33). How-
ver, this difference did not reach signiﬁcance, U = 370.5,
910 M. Biria, F.-X. Huang and Y. Worbe et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 p = 0.056. There was no signiﬁcant difference for the age at
presentation between the two groups U = 742, p = ns. 
The χ2 test was performed to assess the differences be-
tween groups with gender, comorbidities with other psychi-
atric disorders, impact of a lower birth weight, family his-
tory of psychosis and OCD, hand dominance, current smok-
ing and whether the psychosis was triggered by drug use, as
these variables were categorical in nature. None of these
associations reached signiﬁcance (see Table 1 ). 
A multiple linear regression was calculated as a second
conﬁrmatory analysis using the whole sample of patients
with OCI total scores as dependant variable and all the risk
factor variables described above. The best model with the
highest adjusted- R 2 was the one with years on clozapine,
gender, father’s age at birth, family history of psychosis and
OCD, treatment dose of clozapine and smoking habit as in-
dependent variables. A signiﬁcant regression equation was
found ( F (12,110) = 1.885, p < 0.5), with an adjusted- R 2 of
0.08. Only treatment dose was a signiﬁcant predictor of the
OCI total score ( t (110) = 2.949, p < 0.001). The family his-
tory of psychosis together with a ﬁrst degree relative OCD
diagnosis seem to also be associated with higher scores of
the OCI total, however, it did not reach signiﬁcance level ( t
(110) = 1.853, p = 0.06). 
4. Discussion 
In this study, we found that schizophrenia patients with
clozapine-induced OCD had a lower subjective wellbeing
score but not a diminished clinician-rated level of function-
ing. In our sample, younger paternal age and higher cloza-
pine dose were signiﬁcant risk factors for developing OCD.
Thus, we identiﬁed fewer risk factors for OCD onset com-
pared to previous studies, which could be due to our very
selective patient selection process. It is of note that we
set restrictive inclusion criteria that considered OCI-R to-
tal score, checking subset, and length of treatment. This
strategy was adopted to minimise the mis-identiﬁcation of
cases. Indeed, sixty-three patients (more than a quarter of
all the cases) were excluded due to having mid-range OCI-
scores, who might have not developed clinical OCD due to
short exposure to clozapine. 
The multiple linear regression analysis in the whole sam-
ple differed in some respects. It still conﬁrmed that role of
treatment dose seems to have a signiﬁcant impact on the
OCI total scores. Nevertheless, we need to be cautious with
this analysis, as when using the whole sample the risk of
mis-identiﬁcation of cases was high. For example, a mid-
range OCI score could actually be a case due to not yet
being on clozapine long enough to manifest, or a non-case
due to a falsely high total OCI-R score from ﬂorid psychotic
symptoms. In addition, there are likely multiple other fac-
tors involved in the development of OCD in schizophrenia,
not least of which are genetic factors ( Schirmbeck and Zink,
2013 ) which have not been explored in this paper. 
Patients with schizophrenia who develop OCD showed
worse functioning as measured by signiﬁcantly lower well-
being scores (as subjectively scored by the patients them-
selves). This is in concordance with previous work ( de Haan
et al., 2013; Seng et al., 2018; Üçok et al., 2014 ), which
used self rated scales to assess quality of life. In our study,a clinician-scored GAF scale was also used. Notably, there
was no signiﬁcant difference between groups. The previ-
ous study not ﬁnding any association between OCS and out-
come measures also used clinician rated quality of life mea-
sure ( Frias et al., 2014 ). However, the clinician rated CGI
scale showed increased depressive scores in the OCD co-
hort, which could be an indicator of the impact of the ad-
ditional diagnosis on patient wellbeing or potentially due to
the greater degree of positive symptoms as they also had
higher CGI-positive scores. There is an indication that clini-
cians can be unaware of the degree to which having OCD can
negatively impact the patients’ lives. The lack of awareness
can therefore lead to patients not receiving adequate treat-
ment for their OCD symptoms. The reasons for a lack of in-
sight could be inadequate screening, of both patient’s OCD
symptoms and also their personal concerns. Increasing the
awareness of the comorbidity as well as the routine use of
screening tools might be of help to identify and treat these
patients. 
In the OCD group, we found higher CGI-positive scores,
implying greater degree of positive symptoms of schizophre-
nia in the OCD cohort compared to non-OCD group. This
could be consistent with a cognitive theory of the de-
velopment of OCD in anti-psychotic induced schizophrenia
( Fernandez-Egea et al., 2018 ). We have previously found
that checking was the most prevalent symptom that devel-
oped after clozapine treatment. Pending of further replica-
tion, it was proposed that there may be two OCD stages
in clozapine-treated psychosis. The initial goal directed
checking behaviour in OCD was triggered by positive
symptoms of psychosis i.e. checking due to delusional
hypervigilance. Once the obsessional positive symptoms
are improved, and perhaps due to the potent clozapine-
induced anti-serotoninergic action, the residual checking
phenomenon became part of the habit, developing a full
OCD. Therefore, whether a patient has positive symptoms
initially, could affect how likely they are to develop on-
going checking behaviour. Those exhibiting mainly posi-
tive schizophrenia symptoms at the beginning being more
likely to have it incorporated into the checking behaviour
of OCD. There was a trend for type of initial presentation,
with greater proportion of schizophrenia-OCD cohort having
presented with positive symptoms; however, the association
did not attain statistical signiﬁcance. 
Younger paternal age was the only signiﬁcant socio-
demographic factor associated with the onset of OCD symp-
toms in patients with schizophrenia, which is a novel ﬁnd-
ing. It is in contrast with the only existing study that
showed an increased OCD risk with increasing paternal age
( Wu et al., 2012 ). However, this study did not study OCD
development in existing schizophrenia. 
The higher treatment doses of clozapine in the OCD
group replicates previous ﬁndings ( Baytunca et al., 2017;
Fernandez-Egea et al., 2018 ) and remained consistent in
conﬁrmatory multilinear regression analysis. This could
have various explanations such as biological sex, where
males require higher doses, and smoking status, where
smokers require higher doses. However, there were no sig-
niﬁcant differences in sex or smoking status (current or
historical) between groups. Previous studies have shown
an association between OCD severity and clozapine dose
( Mukhopadhaya et al., 2009; Schirmbeck et al., 2011 ). When
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 omparisons are made between the more representative 
lasma clozapine levels and OCD symptoms, which would 
emove the issues of compliance and different pharma- 
okinetics, the association no longer remains signiﬁcant 
 Fernandez-Egea et al., 2018; Schirmbeck et al., 2011 ).
he severity of positive symptoms could be a confound- 
ng factor in the relationship between clozapine dose and 
CD severity, due to more severe symptoms of schizophre- 
ia in the OCD group leading to increased requirement of
lozapine. 
.1. Limitations 
here were strengths in this study, such as the compara-
ively larger number of subjects available, and the use of
any well validated scoring scales. However as this is a 
ross sectional study, we are unable to take a longitudi-
al view to explore causality. We were also unable to carry
ut genetic studies or neuro-imaging, due to the origin of
he data being from the routine clinic work. These points 
an however be used in preparation for future studies e.g.
nto genetic associations which has been planned as a fol-
ow up study to explore causality. Assessing family history 
n our sample was also difﬁcult, due to the information
ource being the patients themselves. Patients were pre- 
enting to clinic with symptoms of psychosis, so their rec-
llections may not have been an accurate representation. 
his could explain why our ﬁndings did not replicate some 
f the previous results ( Fontenelle et al., 2012; Poyurovsky 
t al., 2005 ). 
.2. Conclusion 
n conclusion, an additional comorbidity of OCD signiﬁcantly 
owers the wellbeing of schizophrenia patients on subjec- 
ive scales, especially those with higher positive and higher 
epressive symptoms. It is clear that there is also an in-
ongruence between physician reported and patient re- 
orted quality of life results. Further research could be 
arranted, with increased clinician screening for OCD in 
eviews, and using both types of tools in screening as a goal
n the clinical setting. With regards to risk factors, there
ere very few speciﬁc markers, either clinical or socio- 
emographic which could account for the development of 
CD in schizophrenia. Although paternal age and clozap- 
ne dose were signiﬁcant, their effects did not account for
nough of the difference between groups. The possibility 
f a positive family history being associated with OCD de-
elopment shows there is scope for future studies based on 
maging and genetic studies to further closely investigate 
ausality. 
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